Lord Mendelsohn

To ask Her Majesty's Government what data they have, if any, on the success of treatments provided by COVID Medicines Delivery Units in the UK; and whether they are looking at the data on patients unable to access a CMDU and their outcomes.

To ask Her Majesty's Government what data outcomes are being collected by the COVID-19 Medicines Delivery Unit following the administration of (1) anti-virals, and (2) Sotrovimab, to COVID-positive patients; and when this data will be published.

To ask Her Majesty's Government what data they hold on the patients who are eligible to receive emergency COVID treatments; and if they do not hold any, how they plan to ensure this is collated so patients know in advance of their eligibility and can be t...

To ask Her Majesty's Government whether access to Evusheld will form part of their commitment to providing early access to (1) life-saving, and (2) cutting-edge, medicines through the Innovative Medicines Fund.

To ask Her Majesty's Government what plans they have (1) to review the treatment options for immune-compromised individuals, and (2) to deploy Bebtelovimab as a treatment for such patients.

To ask Her Majesty's Government what assessment they have made of whether their strategy to protect immuno-compromised individuals is over reliant on (1) second line treatments using Sotrovimab, and (2) fourth line treatments using Molnupiravir.

To ask Her Majesty's Government what budget they have set for the purchase of new Antiviral or Monoclonal Antibody drug treatments for COVID-19, including (1) those under current review like Evusheld, and (2) those under future review by the COVID-19 Anti...

To ask Her Majesty's Government whether they are considering the purchase of the Monoclonal Antibody drug Beblitovimab; and other than Evusheld, whether they have any similar drugs under consideration.

To ask Her Majesty's Government whether any delay in purchasing drugs such as Evusheld or Beblitovimab is because of budget limitations; and whether they are will now allocate funding to purchase these new treatments.

To ask Her Majesty's Government, further to the Written Answer by the Parliamentary Under-Secretary of State for the Department of Health and Social Care on 20 April (151279), what estimate they have made of when the UK Health Security Agency (UKHSA) will...

To ask Her Majesty's Government whether they will review the (1) operation of, and (2) access to, the COVID Medicines Delivery Unit (CMDU) system, with particular reference to the role of the 119 telephone number in that process.

To ask Her Majesty's Government what plans they have to enable a system whereby COVID Medicines Delivery Units (1) can be contacted by patients directly for emergency treatment, and (2) have direct access to patient medical records so it can give the appr...

To ask Her Majesty's Government what assessment they have made of the number of individuals who are continuing to shield due to their immunocompromised condition.

To ask Her Majesty's Government whether clinical guidelines have been produced about the prescription of longer courses of anti-virals for refractory infections in immunocompromised individuals; if not, what assessment they have made of the impact of a la...

To ask Her Majesty's Government, further to the Written Answers by Lord Kamall on 18 May (HL158 and HL159) and 20 May (HL160), what steps they are taking to improve the data they need to ensure that they can (1) make informed decisions regarding policies ...

To ask Her Majesty's Government who is responsible for leading the COVID-19 enhanced protection programme (EPP); and what is the process for (1) charities, and (2) patient organisations, to be designated as stakeholders for the programme.

To ask Her Majesty's Government what plans they have to (1) communicate, and (2) consult, with (a) charities, and (b) patient organisations, as part of the COVID-19 enhanced protection programme (EPP); and what format this will take.

To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 27 April (HL7561), what conclusions they have reached following meetings with groups representing the immunocompromised community on how they can be involved in (1) creating,...

To ask Her Majesty's Government what guidance they have given to Work Coaches for recommending employment requiring in-person attendance to immunocompromised individuals.

To ask Her Majesty's Government when they will appoint a ministerial lead specifically responsible for the immunocompromised in order to improve future (1) policy, (2) communication, and (3) guidance, for that group.